Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, whose common stock trades on the Nasdaq. It focuses on developing and commercializing therapies for autoimmune and inflammatory diseases.

Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb, which are found on B cells. By engaging both targets, the drug is intended to inhibit the activity of B-lineage cells that drive many autoimmune conditions without depleting them.

Zenas has studied obexelimab in several indications, including IgG4-related disease, multiple sclerosis and systemic lupus erythematosus. The company builds its pipeline largely by in-licensing promising drug candidates and developing them through late-stage clinical trials. It completed its initial public offering in 2024.